Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)

To see complete record on, please visit this link

Id: NCT05646303

Organisation Name: Clairvoyant Therapeutics

Overal Status: Recruiting

Start Date: November 2, 2022

Last Update: December 12, 2022

Lead Sponsor: Clairvoyant Therapeutics

Brief Summary: The goal of this clinical trial is to investigate treatment with psilocybin and psychotherapy for the treatment of people with Alcohol Use Disorder (AUD). The main question[s] it aims to answer are:

Does treatment with psilocybin and therapy help reduce alcohol consumption more than placebo and therapy?
Is treatment with psilocybin and therapy safe for participants?

Participants will

Attend 13 study visits
Take part in therapy sessions including 2 treatment sessions with either psilocybin or placebo
Record their daily alcohol consumption on study specific device

Researchers will compare psilocybin and placebo groups to see if alcohol consumption is decreased.

  • Alcohol Use Disorder

Total execution time in seconds: 0.28864908218384